Recent studies into retatrutide, a dual agonist for GLP-1 and GIP receptors, are demonstrating significant effects in treating obesity and type 2 disease. Preclinical data suggest a distinct mechanism contributing to https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/